Blue Jays Ink Nic Enright to Two-Year Deal, Eye 2027 Bullpen Boost

The Toronto Blue Jays took a long-term approach to strengthening their bullpen Wednesday by signing right-handed reliever Nic Enright to a two-year minor league deal. The move underscores the organization’s forward-looking strategy, focusing on 2027 while maintaining roster flexibility in 2026.

Enright, 28, will spend the entirety of next season rehabbing from Tommy John surgery. The minor league structure allows Toronto to oversee his recovery without using a 40-man roster spot, giving the team control over a promising arm while minimizing short-term risk.

The former Cleveland Guardians reliever quietly emerged as a reliable late-inning option in 2025. Over 31 innings, he posted a 2.03 ERA and limited hard contact, showcasing the skills that made him an attractive low-risk investment despite his recent surgery.

Beyond performance metrics, Enright’s personal story adds a layer of resilience to the signing. Having previously overcome Hodgkin lymphoma, he reestablished himself as a major league pitcher before facing another career hurdle with elbow reconstruction.

1. Enright’s Performance and Potential

During the 2025 season, Enright quietly demonstrated his value in the Guardians’ bullpen. His 2.03 ERA and ability to suppress hard contact positioned him as a dependable late-game option, drawing attention from teams looking to bolster their relief corps. Despite undergoing Tommy John surgery late in the season, his prior effectiveness made him a compelling candidate for Toronto. The Blue Jays viewed him as a low-risk, high-upside signing who could contribute meaningfully once fully recovered. The minor league contract provides the team with flexibility while allowing Enright to focus on rehabilitation. The structure gives the Blue Jays time to monitor his progress and plan for a potential 2027 return without pressure from immediate major league expectations. The deal also represents an opportunity for the organization to acquire a proven arm at a controlled cost, aligning with Toronto’s broader strategy of blending depth, patience, and long-term upside in their pitching staff.

2. Resilience Off the Field

Enright’s journey to this point has been defined by determination. Earlier in his career, he overcame a Hodgkin lymphoma diagnosis, returning to professional baseball and establishing himself as a capable major league reliever. The combination of personal grit and professional skill makes him a particularly intriguing addition for the Blue Jays. He has faced major health setbacks before and returned to perform at a high level, a track record that bodes well for his post-Tommy John recovery. Toronto’s signing of Enright also signals the value the organization places on character and resilience, not just statistics. His story offers inspiration and a blueprint for overcoming adversity while maintaining professional excellence. The two-year deal balances risk with potential reward, giving both player and team a chance to succeed in a controlled environment that emphasizes preparation for future seasons.

3. Strategic Move for Toronto

For the Blue Jays, securing Enright now is a proactive step in bullpen management. The club can add a high-upside arm for 2027 without immediate roster strain, ensuring depth while planning for long-term pitching needs. The organization’s strategy reflects a broader philosophy of patience and calculated investment. By acquiring Enright while he rehabs, Toronto maintains flexibility in 2026 while positioning itself to benefit from his abilities once fully healthy. This approach aligns with the Blue Jays’ focus on building a sustainable, adaptable roster. They are prioritizing depth and long-term planning, recognizing that strategic timing can create advantages in future seasons. Enright’s presence, both on and off the field, could provide leadership and example-setting for younger pitchers in the organization as they navigate development and adversity.